• news.cision.com/
  • aXichem AB/
  • aXichem presents interim report for the second quarter of 2023 on Wednesday 23 August at 14:00

aXichem presents interim report for the second quarter of 2023 on Wednesday 23 August at 14:00

Report this content

aXichem AB (publ), a pioneer in the development and marketing of natural analogue industrial chemicals, publishes its interim report for the second quarter of 2023 on Wednesday, August 23, 2023. On the same day at 2:00 p.m., the company invites you to a teleconference with CEO Torsten Helsing.

After the conference, there will be a question-and-answer session. The presentation is held in Swedish. It is possible to follow the conference via computer or mobile devices.

To register for the webinar, please register via the following link: https://attendee.gotowebinar.com/register/6339509601048976216

The number of places is limited, so we recommend registering well in advance to secure a place.

After the conference, the teleconference and the presentation material will be available on the company's website, aXichem, and on the Västra Hamnen Corporate Finance channel on YouTube.

The information was submitted, through the care of the contact person below, for publication on 22 August 2023, at 10:30 am CET.

Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se

About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Västra Hamnen Corporate Finance AB is Certified Adviser. More information is available at
www.axichem.com.